Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 47,950 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 47,950 shares of the business’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $1.22, for a total transaction of $58,499.00. Following the sale, the insider directly owned 5,959,172 shares of the company’s stock, valued at approximately $7,270,189.84. The trade was a 0.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Stock Down 1.6%

Shares of NASDAQ:HOWL traded down $0.02 during midday trading on Thursday, hitting $1.20. 647,728 shares of the company’s stock were exchanged, compared to its average volume of 891,846. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.41. The company has a market cap of $58.25 million, a PE ratio of -0.74 and a beta of 0.72. The stock has a 50 day moving average price of $1.61 and a 200-day moving average price of $1.32. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 5.30.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, sell-side analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on HOWL shares. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Bank of America cut their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities dropped their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. Vontobel Holding Ltd. purchased a new position in Werewolf Therapeutics in the first quarter valued at about $34,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after buying an additional 23,852 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at approximately $71,000. MPM Asset Management LLC lifted its stake in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares in the last quarter. Finally, MPM Bioimpact LLC lifted its stake in shares of Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after buying an additional 20,799 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.